Cryo-Cell International Inc. (CCEL) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cryo-Cell International Inc. (CCEL:NYSE), powered by AI.

Current Price
$3.45
P/E Ratio
-11.5
Market Cap
28M
Sector
Healthcare
What is the Cryo-Cell International Inc. stock price forecast?

Cryo-Cell International Inc. is currently trading at $3.45. View real-time AI analysis on Alpha Lenz.

What is Cryo-Cell International Inc. insider trading activity?

View the latest insider trading data for Cryo-Cell International Inc. on Alpha Lenz.

What is Cryo-Cell International Inc.'s P/E ratio?

Cryo-Cell International Inc.'s P/E ratio is -11.5.

Cryo-Cell International Inc.

NYSE · CCEL
$3.45-0.15(-4.17%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Cryo-Cell International Inc.'s future dividend policy...
Alpha Chat Insight

Cryo-Cell International Inc. trades at a P/E of -11.5 (undervalued) with strong ROE of 15.3%.

Ask for details

Company Overview

Cryo-Cell International Inc. is a prominent biotechnology company that specializes in cord blood and tissue banking services. Established with a focus on providing families with the opportunity to preserve vital biological resources, Cryo-Cell collects and stores umbilical cord blood and tissue at the time of a child's birth. These stored cells can potentially be used in future medical treatments due to their ability to differentiate into various cell types. The primary purpose of Cryo-Cell is to offer reliable and accessible solutions for parents wishing to safeguard their children's health against potential future illnesses, such as blood disorders and certain genetic diseases. Operating within the healthcare and biotech sectors, Cryo-Cell International Inc. plays a crucial role in the rapidly evolving field of regenerative medicine, contributing to advancements in cellular therapies and research. With its headquarters in Oldsmar, Florida, the company is a significant participant in the biotechnology industry, known for its emphasis on innovation, quality control, and adherence to rigorous industry standards. As a trusted entity in its domain, Cryo-Cell remains committed to expanding its scientific capabilities and enhancing the scope of its services, thereby impacting the broader medical and scientific communities.

CEOMr. David I. Portnoy
SectorHealthcare
IndustryMedical Care Facilities
Employees82

Company Statistics

FY 2025

Profile

$27.84MMarket Cap
$31.57MRevenue
0.00Shares Out
82Employees

Margins

76.63%Gross
19.84%EBITDA
15.34%Operating
-7.40%Pre-Tax
-7.70%Net

Valuation

-11.46P/E
-1.50P/B
0.88EV/Sales
6.24EV/EBITDA
5.30P/FCF

Growth (CAGR)

1.33%Rev 3Yr
0.27%Rev 5Yr
2.77%Op Inc 3Yr
-7.12%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.84%ROA
15.27%ROE
-0.43%ROIC

Financial Health

$319.03KCash & Cash Equivalents
$80.02MNet Debt
-431.77%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cryo-Cell International Inc. (ticker: CCEL) is a company listed on NYSE in the Healthcare sector (Medical Care Facilities). It has approximately 82 employees. Market cap is $28M.

The current price is $3.45 with a P/E ratio of -11.46x and P/B of -1.5x.

ROE is 15.27% and operating margin is 15.34%. Annual revenue is $32M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cryo-Cell International Inc. (CCEL) Stock Forecast 2026 $3.45 — Price, Financials & Analyst Targets | Alpha Lenz